Pyramid Analytics Named CRN Channel Awards 2022 Finalist
15.9.2022 10:00:00 EEST | Business Wire | Press release
Pyramid Analytics (Pyramid), a pioneering decision intelligence platform provider, is a CRN Channel Awards 2022 finalist in the Emerging Vendor of the Year category. The Emerging Vendor of the Year category recognises new and emerging organisations which have successfully supported the growth of their channel partners in the UK. CRN reported a record number of award entries. Expanding channel partnerships with complementary technology companies, independent software vendors (ISV), consulting firms, value-added resellers (VAR) and systems integrators (SI) is a strategic priority. Pyramid has expanded its Alliances team and partner recruitment capabilities, invested in partner training and development, and launched joint go to market programs.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220915005045/en/
Bill Clayton, Vice President, Global Alliances for Pyramid Analytics (Photo: Business Wire)
Key Points:
- Pyramid Analytics is a finalist in the Emerging Vendor of the Year category of the CRN Channel Awards 2022.
- The channel partner programme is the backbone of Pyramid’s UK operations, accounting for a significant segment of UK revenue.
- Pyramid partners in the UK include Amplifi, AND Grow International Ltd, Ascot London Consulting Limited, AWS, Delaware, Snap Analytics.
- The winners of the CRN Channel Awards 2022 will be announced at an award ceremony on November 10 at Evolution London in the heart of London’s iconic Battersea Park.
- To learn more about becoming a Pyramid partner in the UK & Ireland, contact bill.clayton@pyramidanalytics.com.
Pyramid Analytics Demonstrates its Commitment to and Value for Channel Partners
The CRN Channel Awards is one of the highest accolades in the UK channel. It recognises excellence across the UK channel landscape, with categories covering Vendors, Distributors and Resellers. All entries face a rigorous judging process from industry leaders. The judges this year recognised the particularly “strong competition” with several of the categories receiving a record number of entries.
Being shortlisted for the award is a culmination of Pyramid’s four and a half years of commitment to the UK economy, with the growth of its channel partnerships at the core of its business strategy and success. 2022 has been the most momentous year for Pyramid in the UK with the hiring of Tom Warren as Managing Director for UKI and the announcement of a $120 million Series E funding round announcement at a special event at Tower Bridge.
Channel partners are critical for Pyramid’s ability to continue to grow in a scalable manner, in turn offering them access to pioneering innovative technology that can transform their business. Pyramid understands that for outstanding growth to be achieved for the company and for its channel partners, its partners should be thoroughly supported with training to develop in-depth knowledge and insights. Pyramid’s partner portal is vital in delivering learning, development and growth value for Pyramid and its partners.
Decision Intelligence is the Next Big Data Analytics Innovation
The next major innovation in analytics is Artificial Intelligence (AI). Applying AI across Data Prep, Business Analytics, and Data Science is what separates Decision Intelligence from traditional business intelligence tools such as Microsoft Power BI, Qlik, and Tableau. AI lowers the skills barrier by automating the highly technical work needed to prepare and analyze data and create and share reports and dashboards.
The Pyramid Decision Intelligence Platform delivers data-driven insights for anyone to make faster, more intelligent decisions. The Pyramid Platform provides instant access to any data, enables automated governed self-service for any person, and serves any analytics need, from the simple to the sophisticated. By uniquely combining Data Prep, Business Analytics, and Data Science with AI guidance in a single environment, the Pyramid Platform reduces cost and complexity while accelerating growth and innovation. This enables a strategic, organization-wide approach to Business Intelligence and Analytics.
Quotes
Tom Warren , Vice President of UKI, Pyramid Analytics: “The entire Pyramid team is delighted and proud to have been shortlisted for the CRN Channel Awards. To be shortlisted as an Emerging Vendor of the Year really is the icing on the cake for what has been a brilliant year for the company and for our channel partners. The fact the Series E funding round was announced in the UK was a strong signal of our intent and commitment to the UK – and we’re only getting started. I would like to take this opportunity to say a massive thank you to CRN for this recognition, to the Pyramid team and our amazing channel partners who believe in us and stand by us.”
Bill Clayton , Vice President of Global Partner Sales, Pyramid Analytics: “The CRN Channel Awards are closely watched by everyone in the UK channel ecosystem, and it’s a momentous occasion for the whole Pyramid family to be nominated. For Pyramid, our channel partnerships have become an essential cornerstone of our business. Our highly productive and effective work with channel partners has forged a host of mutually beneficial relationships that have driven growth for all involved across the UK. Channel partners are now the core of Pyramid’s business. The upcoming growth and expansion of the company is firmly embedded with our channel partners, and I look forward to making that future a reality.”
About Pyramid Analytics
Pyramid is what’s next in analytics. Our unified decision intelligence platform delivers insights for anyone to make faster, more informed decisions. It provides direct access to any data, enables governed self-service for any person, and serves any analytics need in a no-code environment. The Pyramid Decision Intelligence Platform uniquely combines Data Prep, Business Analytics, and Data Science in a single environment with AI guidance, reducing cost and complexity while accelerating growth and innovation. The Pyramid Platform enables a strategic, organization-wide approach to Business Intelligence and Analytics, from the simple to the sophisticated. Schedule a demo.
Pyramid Analytics is incorporated in Amsterdam and has regional headquarters in global innovation and business centers, including London, New York City, and Tel-Aviv. Our team lives worldwide because geography should not be a barrier to talent and opportunity. Investors include H.I.G. Growth Partners, Jerusalem Venture Partners (JVP), Sequoia Capital, and Viola Growth. Learn more at Pyramid Analytics.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220915005045/en/
Contact information
UK
Alex Izza
Resonance
07591899654
pyramidanalytics@resonancecrowd.com
US
Heather Racicot
Resonance
+1 360-632-5616
pyramidanalytics@resonancecrowd.com
Chas Kielt
Vice President of Global Corporate Communications, Pyramid Analytics
617.687.3371
chas.kielt@pyramidanalytics.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Provides Progress Update Regarding RelabotulinumtoxinA Regulatory Submission in the United States1.7.2026 08:00:00 EEST | Press release
Galderma (SIX: GALD) today provided progress updates regarding the regulatory review of its pending Biologics License Application (“BLA”) for RelabotulinumtoxinA with the U.S. Food and Drug Administration (“FDA”). The Company has received a Complete Response Letter (CRL) from the FDA with comments related to observations during manufacturing site inspection and analytical method optimization. As part of its review, the FDA conducted a Pre-License Inspection (PLI) of Galderma’s manufacturing site. All other aspects of the BLA, including safety- and efficacy-related parts, did not solicit deficiencies to be addressed. The FDA made observations during the PLI for which Galderma is putting in place corrective and preventive actions. Galderma will also be seeking further guidance through continued open dialogue with the FDA toward resolution of the relevant observations. Galderma plans to rapidly respond to the CRL and advancing RelabotulinumtoxinA in the U.S. remains a top priority. The ob
EVE Energy Showcases All-Scenario Energy Storage Solutions at The Smarter E Europe 20261.7.2026 04:45:00 EEST | Press release
EVE Energy unveiled its Mr. Big Family series, a 6.9+ MWh energy storage system, and all-scenario energy storage solutions at Intersolar Europe in Munich. Drawing on traceable large-cell technology, proven large-scale energy storage project delivery experience, and global delivery capabilities, the company is addressing Europe's diverse energy storage requirements across utility-scale, commercial & industrial (C&I ), and data center segments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260630889717/en/ EVE Energy showcases its Mr. Giant 3.0 6.9+ MWh energy storage system at The Smarter E Europe 2026 in Munich, Germany Advancing Large-Cell Technology with Global Project Validation As one of the first companies to focus on large-capacity energy storage cells, EVE Energy has iteratively upgraded its cell platform from 560 Ah and 628 Ah to 702 Ah, adhering to a stacking process route throughout. At the exhibition, the Mr. Gia
Bending Spoons S.p.A. announces pricing of initial public offering1.7.2026 02:56:00 EEST | Press release
Bending Spoons S.p.A. (“Bending Spoons”), a leading technology company, today announces the pricing of its initial public offering (“IPO”) at $29.00 per share. A total of 57,971,015 ordinary shares are being offered, of which 34,398,640 shares are being offered by Bending Spoons and 23,572,375 shares are being offered by certain selling shareholders (the “Selling Shareholders”). Bending Spoons will not receive any proceeds from any sale of shares by the Selling Shareholders. The shares are expected to begin trading on the Nasdaq Global Select Market under the ticker symbol “BSP” on July 1, 2026. The offering is expected to close on July 2, 2026, subject to customary closing conditions. In addition, Bending Spoons and the Selling Shareholders granted the underwriters an option to purchase up to an additional 5,244,026 ordinary shares from Bending Spoons and up to an additional 3,451,626 ordinary shares from the Selling Shareholders at the initial public offering price, less underwriting
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 19:19:00 EEST | Press release
Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease and lung cancer,” she added. “More broadly, it reinforces the agency’s science-based approach to evaluating products across the co
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 18:00:00 EEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom